◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ProShares UltraShort Nasdaq Biotechnology (BIS) ETF Overview

Name: ProShares UltraShort Nasdaq Biotechnology (BIS) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Trading--Inverse Equity · DATA UPDATED 2026-08-31

ProShares UltraShort Nasdaq Biotechnology (BIS) is an exchange-traded fund managed by ProShares in the "Trading--Inverse Equity" category. It manages roughly $2 million in assets.

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.

Interactive chart & fund stats →

BIS Fund Statistics

Expense ratio	0.95%
Trailing yield	5.61%
Assets under management	$2 million
Fund category	Trading--Inverse Equity
Fund family	ProShares
Inception	2010-04-06

The live price chart, fund profile and news are in the interactive BIS viewer.

Other Companies in Trading--Inverse Equity

EEV · ProShares UltraShort MSCI Emerging Markets — $3 million
MZZ · ProShares UltraShort MidCap400 — $3 million
PALD · Direxion Daily PANW Bear 1X Shares — $2 million
BZQ · ProShares UltraShort MSCI Brazil Capped — $2 million
SMDD · ProShares UltraPro Short MidCap400 — $2 million
SMZ · Tradr 2X Short Smr Daily ETF — $2 million
CSCS · Direxion Daily CSCO Bear 1X Shares — $2 million
CARD · Max Auto Industry -3X Inverse Leveraged ETN — $1 million

← BIRK All “B” companies BITA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.